A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Mark A. Chambers, D. Craig Wright, Joan Brisker, Ann Williams, Graham Hatch, Dolores Gavier-Widén, Graham Hall, Philip D. Marsh, R. Glyn Hewinson

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

Original languageEnglish
Pages (from-to)1063-1071
Number of pages9
JournalVaccine
Volume22
Issue number8
DOIs
Publication statusPublished - 25 Feb 2004

Keywords

  • Liposome
  • M. bovis
  • Vaccine

Fingerprint

Dive into the research topics of 'A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis'. Together they form a unique fingerprint.

Cite this